Treatment of type 2 diabetes with incretin-based therapies

Department of Endocrinology, Hvidovre Hospital and University of Copenhagen, 2650 Hvidovre, Denmark.
The Lancet (Impact Factor: 45.22). 10/2008; 373(9662):438-9. DOI: 10.1016/S0140-6736(08)61247-7
Source: PubMed
0 Reads
  • Source
    • "Type 2 DM can be treated by incretin injection [33]. Incretin-based therapies have been applied in this type of DM successfully [34]. The typical incretin is glucagon-like peptide 1 (GLP-1) [35]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Glucagon-like peptide-1 (GLP-1) is a promising target for diabetes mellitus (DM) therapy and reduces the occurrence of diabetes due to obesity. However, GLP-1 will be hydrolyzed soon by the enzyme dipeptidyl peptidase-4 (DPP-4). We tried to design small molecular drugs for GLP-1 receptor agonist from the world's largest traditional Chinese medicine (TCM) Database@Taiwan. According to docking results of virtual screening, we selected 2 TCM compounds, wenyujinoside and 28-deglucosylchikusetsusaponin IV, for further molecular dynamics (MD) simulation. GLP-1 was assigned as the control compound. Based on the results of root mean square deviation (RMSD), solvent accessible surface (SAS), mean square deviation (MSD), Gyrate, total energy, root mean square fluctuation (RMSF), matrices of smallest distance of residues, database of secondary structure assignment (DSSP), cluster analysis, and distance of H-bond, we concluded that all the 3 compounds could bind and activate GLP-1 receptor by computational simulation. Wenyujinoside and 28-deglucosylchikusetsusaponin IV were the TCM compounds that could be GLP-1 receptor agonists.
    Evidence-based Complementary and Alternative Medicine 05/2014; 2014(7285):385120. DOI:10.1155/2014/385120 · 1.88 Impact Factor
  • Source
    • "Therefore the dosage of insulin should be adjusted while adding and removing these drugs from the patients’ prescriptions. Dipetidyl protease inhibitors (the gliptins), a comparatively newer class of hypoglycemic agents, have a theoretical possibility of reducing immunocompetence because of their mechanism of action [32]. This effect could possibly worsen the outcome of patients with TB. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Developing countries shoulder most of the burden of diabetes and tuberculosis. These diseases often coexist. Suboptimal control of diabetes predisposes the patient to tuberculosis, and is one of the common causes of poor response to anti-tubercular treatment. Tuberculosis also affects diabetes by causing hyperglycemia and causing impaired glucose tolerance. Impaired glucose tolerance is one of the major risk factors for developing diabetes. The drugs used to treat tuberculosis (especially rifampicin and isoniazid) interact with oral anti-diabetic drugs and may lead to suboptimal glycemic control. Similarly some of the newer oral anti-diabetic drugs may interact with anti-tuberculosis drugs and lower their efficacy. Therefore diabetes and tuberculosis interact with each other at multiple levels - each exacerbating the other. Management of patients with concomitant tuberculosis and diabetes differs from that of either disease alone. This article reviews the association between diabetes and tuberculosis and suggests appropriate management for these conditions.
    Journal of Diabetes and Metabolic Disorders 12/2012; 11(1):28. DOI:10.1186/2251-6581-11-28
  • Source
    • "Recently developed pharmacological therapies show improved control of blood glucose levels in the treatment of Type II diabetics (e.g. Liraglutide (NN2211) [48] [49]) but Type I diabetics are dependent on insulin injection which results in fluctuations in their physiological blood glucose levels. Elevated blood glucose levels triggers the onset of secondary microvascular and neurologic complications such as cardiovascular disease, glomerularnephritis and proliferative diabetic retinopathy (PDR) [50]. "

    Biomaterials Developments and Applications : Advances in Biology and Medicine Series, Edited by Bourg H and Lisle A, 01/2010: chapter Biomaterials in Dentistry and Medicine: pages 231-289; Nova Publishers NY., ISBN: ISBN: 978-1-60876-476-1
Show more